A roundtable discussion with Drs Carla Casulo and John P Leonard
on recent developments in the treatment of follicular lymphomas,
including the following topics:
Current management of newly diagnosed follicular lymphoma (FL);
choice of observation versus rituximab monotherapy (00:00)
Association between vitamin D insufficiency and outcomes for
patients with FL 5m41s
Efficacy and tolerability of obinutuzumab/bendamustine for
patients with newly diagnosed FL (9:44)
Activity of lenalidomide/rituximab (R2) in patients
with FL (15:56)
Biology of FL; criteria for initiating therapy after diagnosis
(20:55)
Results of the Phase III GALLIUM study of obinutuzumab or
rituximab, each in combination with chemotherapy, followed by
maintenance obinutuzumab or rituximab for patients with untreated,
advanced FL (31:02)
Phase III RELEVANCE trial evaluating R2 versus
rituximab/chemotherapy, each followed by maintenance rituximab, as
first-line therapy for advanced FL (34:58)
Selection and sequencing of therapies for relapsed/refractory
FL; management of early progression of disease (41:07)
Biologic predictors of early relapse; role of transplant for
patients with FL (47:20)
Activity and tolerability of CAR (chimeric antigen receptor)
T-cell therapies for FL (54:39)
Response to the PI3 kinase inhibitor umbralisib in combination
with obinutuzumab for relapsed FL (58:02)
Outcomes for patients with early relapse of FL in the National
LymphoCare Study (1:04:35)
Integration of the PI3 kinase inhibitors idelalisib, copanlisib
and duvelisib into the management of FL (1:12:18)
Mechanism of action, efficacy and tolerability of the recently
approved EZH2 inhibitor tazemetostat for relapsed/refractory FL
(1:22:01)
Results of the Phase II ZUMA-5 study of axicabtagene
ciloleucel for patients with relapsed/refractory indolent
non-Hodgkin lymphoma (1:26:32)
Biologic rationale for the use of the novel bispecific antibody
mosunetuzumab for relapsed/refractory FL (1:30:40)
Novel agents and approaches under investigation for patients
with FL (1:34:58)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.